Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 8/2016

01-08-2016 | Brief report

Vascular morphology differentiates prostate cancer mortality risk among men with higher Gleason grade

Authors: Meng Yang, Ke Zu, Lorelei A. Mucci, Jennifer R. Rider, Michelangelo Fiorentino, Steven K. Clinton, Massimo Loda, Meir J. Stampfer, Edward Giovannucci

Published in: Cancer Causes & Control | Issue 8/2016

Login to get access

Abstract

Background

Higher Gleason grade is associated with prostate cancer mortality; however, there is significant heterogeneity in this association. We evaluated whether vessel morphology, a biomarker of angiogenesis, aided in distinguishing mortality risks among men with high Gleason grading.

Methods

We characterized vessel morphology (area and irregularity) among 511 patients diagnosed with prostate cancer during 1986 to 2000, re-reviewed Gleason grade, and followed men through 2012. Men were grouped according to integrated vessel lumen irregularity and vessel area across Gleason grade. The more angiogenic group was identified as those with more irregular vessel lumen and smaller vessel area. Crude rates (95 % confidence intervals) and survival probability were estimated across Gleason grade and vessel morphology.

Results

During a median 14-year follow-up, 62 men developed bone metastases or died of prostate cancer. Lethality rates were uniformly low within Gleason grade categories 6 and 7(3 + 4), regardless of vessel morphology. However, among men with Gleason grades of 7(4 + 3) or 8–10, the more angiogenic group was associated with fourfold higher risk of lethal outcomes compared to those with less angiogenic potential. Ten-year survival probability ranged from 95 to 74 % according to the extent of vessel morphology (p < 0.0001, log-rank test).

Conclusions

Vessel morphology may aid Gleason grading in predicting prostate cancer mortality risks among men diagnosed with high-grade Gleason cancers.
Appendix
Available only for authorised users
Literature
1.
Stark JR, Perner S, Stampfer MJ et al (2009) Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol 27:3459–3464CrossRefPubMedPubMedCentral
2.
Sakr WA, Grignon DJ, Crissman JD et al (1994) High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20–69: an autopsy study of 249 cases. In Vivo 8:439–443PubMed
3.
Andren O, Fall K, Franzen L, Andersson SO, Johansson JE, Rubin MA (2006) How well does the Gleason score predict prostate cancer death? a 20-year followup of a population based cohort in Sweden. J Urol 175:1337–1340CrossRefPubMed
4.
Giovannucci E (2011) Commentary: serum lycopene and prostate cancer progression: a re-consideration of findings from the prostate cancer prevention trial. Cancer Cause Control 22:1055–1059CrossRef
5.
Ahmed HU, Arya M, Freeman A, Emberton M (2012) Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy? Lancet Oncol 13:e509–e517CrossRefPubMed
6.
Mucci LA, Powolny A, Giovannucci E et al (2009) Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study. J Clin Oncol 27:5627–5633CrossRefPubMedPubMedCentral
7.
Pettersson A, Graff RE, Bauer SR et al (2012) The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomark Prev 21:1497–1509CrossRef
8.
Graff RE, Pettersson A, Lis RT et al (2016) Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression. Am J Clin Nutr 103:851–860CrossRefPubMed
9.
West AF, O’Donnell M, Charlton RG, Neal DE, Leung HY (2001) Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer. Br J Cancer 85:576–583CrossRefPubMedPubMedCentral
10.
Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353–364CrossRefPubMed
11.
Russo G, Mischi M, Scheepens W, De la Rosette JJ, Wijkstra H (2012) Angiogenesis in prostate cancer: onset, progression and imaging. BJU Int 110:E794–E808CrossRefPubMed
12.
Zu K, Mucci L, Rosner BA et al (2014) Dietary lycopene, angiogenesis, and prostate cancer: a prospective study in the prostate-specific antigen era. J Natl Cancer Inst. 106:djt430CrossRefPubMedPubMedCentral
13.
Li Y, Cozzi PJ (2010) Angiogenesis as a strategic target for prostate cancer therapy. Med Res Rev 30:23–66PubMed
14.
Alhusban A, Al-Azayzih A, Goc A, Gao F, Fagan SC, Somanath PR (2014) Clinically relevant doses of candesartan inhibit growth of prostate tumor xenografts in vivo through modulation of tumor angiogenesis. J Pharmacol Exp Ther 350:635–645CrossRefPubMedPubMedCentral
15.
Metadata
Title
Vascular morphology differentiates prostate cancer mortality risk among men with higher Gleason grade
Authors
Meng Yang
Ke Zu
Lorelei A. Mucci
Jennifer R. Rider
Michelangelo Fiorentino
Steven K. Clinton
Massimo Loda
Meir J. Stampfer
Edward Giovannucci
Publication date
01-08-2016
Publisher
Springer International Publishing
Published in
Cancer Causes & Control / Issue 8/2016
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-016-0782-x

Other articles of this Issue 8/2016

Cancer Causes & Control 8/2016 Go to the issue

Original Paper

Estimating the prevalence of hematological malignancies and precursor conditions using data from Haematological Malignancy Research Network (HMRN)

Original paper

Receipt of mammography recommendations among White and non-White women before and after the 2009 United States Preventive Services Task Force recommendation change

Original paper

Genetic variants in the mTOR pathway and interaction with body size and weight gain on breast cancer risk in African-American and European American women

Original paper

A prospective study of angiogenic markers and postmenopausal breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial

Original paper

Inequalities in cancer incidence and mortality across medium to highly developed countries in the twenty-first century

Short Communication

Framing research for state policymakers who place a priority on cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits